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Focused Workshop 1
Advanced imaging methods for the 
assessment of MS pathogenesis and 
treatment
FW01-1
Insight into the pathogenesis of multiple 
sclerosis using metabolic imaging
O. Ciccarelli
London, United Kingdom
The mechanisms that underlie the pathogenesis of multiple 
sclerosis (MS) are patially understood, and include 
inflammatory demyelination, oxidative stress, mitochondrial 
dysfunction, glutamate excitotoxicity, sodium homeostasis 
imbalance, neuroaxonal degeneration and gliotic response. 
These mechanisms lead to pathological abnormalities, which 
are responsbile for acute and progressive disability.
Metabolic imaging comprises techniques that exploit the 
magnetic resonance properties of atomic nuclei, such as 
protons or sodium ions. These techniques include 
1H-Magnetic Resonance Spectroscopy (MRS) and Sodium 
Imaging. I will describe the insights into the pathogenesis of 
MS which have been provided by MRS and Sodium imaging 
studies. These studies have suggested mitochondrial 
metabolic dysfunction and neuroaxonal loss at the onset of 
acute events, in relapsing remitting MS and in the early stages 
of primary progressive MS, increased mitochondrial activity 
after acute MS lesions, raised total sodium concentration 
within and outside lesions (especially in progressive MS), 
reduced concentration of GABA in the hippocampus and 
sensorimotor cortex in patients with progressive MS than 
healthy controls, increased glutamate levels in acute lesions 
and normal-appearing white matter, abnormalities in the 
glutamatergic pathways in the cervical cord of early primary 
progressive MS (in the absence of extensive spinal cord 
atrophy), and glial activation in T2 lesions and normal-
appearing white matter. Clinical translation of metabolic 
imaging techniques may be useful to answer key questions on 
the pathogenesis of MS. Further technical developments aim 
at improving the sensitivity and specificity of these techiques 
anf at translating them to clinical trials.
Disclosure: OC serves as a consultant for Biogen, Genzyme, 
Roche, GE Healthcare and Novartis (payments are made to 
the institution); she receives an honorarium as Associate 
Editor of Neurology; she receives research funding from 
EPSRC, UKMSS, NMSS, NIHR ULCH BRC and UCL. 
FW01-2
The promise of ultra high field MRI in 
multiple sclerosis
F. Barkhof
Amsterdam, The Netherlands
There is a continuous quest to move MR imaging to higher 
fields strengths as this improves the signal-to-noise ratio 
(SNR). In terms of clinical applocations, field strength 
moved from low field (0.5 Tesla) to high field (3T), as 
reviewed in Neuroradiology (2009;51:279-292). More 
recently, so-called ultra-high field (7T) scanners have 
become available for whole body imaging and has been 
approved by regulators for human applications. MRI at 7T 
provides challenges in terms of signal homogeneity, 
artefacts and limitations in terms of RF deposition, which 
are being overcome slowly. It is an interesting research tool 
that offers new possibilities for niche applications such as 
improved detection of cortical lesions (Brain. 2016 Mar 8. 
pii: aww037. [Epub ahead of print]), which are particularly 
extensive in progressive MS (Neurology. 2015 Nov 
10;85(19):1702-9). The higher SNR can also be used to 
study small structures such as the hippocampus, 
hypothalamus. Due to susceptibility artefacts around 
osseous structures, imaging at 7T in the optic nerve and 
spinal cord is quite challenging. The enhanced susceptibility 
effects at 7T within veins and lesions with iron accumulation 
however is advantageous and helps to differentiate MS from 
other disorders such as Susac syndrome (Mult Scler. 2012 
Nov;18(11):1592-9) and NMO (AJNR Am J Neuroradiol. 
2016 Mar 24).
Disclosure: Consultancy agreements with Roche, Novartis, 
Biogen, Genzyme, Synthon, TEVA. Research support to my 
group from Toshiba, Philips, Novartis, TEVA.  
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FW01-3
Assessing tissue damage and repair in 
multiple sclerosis by positron emission 
tomography
B. Stankoff
Paris, France
Positron emission tomography, a quantitative nuclear 
medicine technology that uses labeled compounds 
recognizing specific biological targets, offers the unique 
opportunity to directly assess some key mechanisms 
involved in MS pathophysiology. Several stilbene and 
benzothiazole derivatives have been repurposed for the 
dynamic imaging by PET of myelin loss and repair in the 
MS brain. Robust non-invasive quantification techniques 
were validated and recently allowed to perform longitudinal 
studies in vivo. A great heterogeneity in individual 
remyelination potential was shown during the relapsing 
remitting phase of the disease, with a close correlation 
between remyelinating ability, neurodegeneration and 
neurological disability. The most popular target for PET 
microglial imaging is the TSPO macromolecular complex, 
which is drastically up-regulated in activated microglial 
cells. PET with the reference compound [11C]-PK11195 
identified diffuse microglial activation in the normal 
appearing white matter and in the cortex of patients with a 
progressive form of MS. To circumvent some weaknesses 
of this tracer, a range of improved second-generation TSPO 
ligands has been developed, and novel fluorinated 
compounds should now allow to disseminate this imaging 
technology to many centres. The central benzodiazepine 
receptor antagonist 11C-Flumazenil (FMZ) is an imaging 
marker of neuronal integrity, and has been used to quantify 
and regionally map the neuronal component of grey matter 
damage in MS, both at the group level and at the individual 
level. The combination of these imaging probes with MRI 
sequences will enable to detangle several key 
pathophysiologic mechanisms that drive disability in MS, 
and will contribute to the development of new therapies. 
Disclosure: Nothing to disclose.
Focused Workshop 2
Genetic approaches in neuropathies
FW02-1
Genotype-phenotype correlations in 
hereditary neuropathies
M. Auer-Grumbach
Graz, Austria
Hereditary neuropathies are clinically and genetically very 
heterogenous with more than 60 genes identified so far. The 
classical and most common form is Charcot-Marie-Tooth 
disease (CMT, also known as motor and sensory neuropathy, 
HMSN), which is characterized by slowly progressive 
weakness and wasting in the distal parts of upper and lower 
limbs, symmetric foot-deformities and variable sensory 
disturbances. The underlying pathological event is 
demyelinating (primarily affecting Schwann cells, CMT1) 
or axonal (primarily affecting axons, CMT2) nerve damage. 
Phenotype-genotype correlation studies have shown, that 
some genetic subtypes are associated with a particular 
phenotype. Knowledge of additional features such as vocal 
cord paralysis, scoliosis, optic atrophy, hearing loss, and 
ulcero-mutilating features amongst others often serves to a 
definite genetic diagnosis. Mutations in known CMT genes 
leading to such complicated phenotypes of hereditary 
neuropathies will be discussed in detail based on case 
reports.
Disclosure: Nothing to disclose.
 
FW02-2
Whole-exome sequencing in patients with 
inherited neuropathies: outcome and 
challenges
J. Baets
Antwerp, Belgium
The genetic diversity of inherited neuromuscular disorders 
such as inherited peripheral neuropathies is extensive and 
recently the more widespread use of next generation 
sequencing (NGS) technologies and most notably whole-
exome sequencing (WES) has accelerated gene discovery 
and genetic diagnosis. Although traditional genetic 
strategies were more bound to the lines of previously 
established knowledge, WES and is powerful enough to be 
truly “disruptive” by rapidly yielding large quantities of 
unbiased genetic data. Genetic heterogeneity now turns out 
to be much more extensive. Expanding disease spectra 
break up the boundaries between disease entities and 
pressurize existing genotype-phenotype correlations to the 
point of making them unintelligible. The unexpected 
identification of (spurious) variations in known and novel 
genes is puzzling. A huge task still waits to establish the 
causal links between this overabundance of genetic 
variation and disease. Still, the absence of a precise genetic 
diagnosis in patients precludes genetic counselling, pre-
implantation genetic diagnosis and ultimately therapy. At 
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the same time WES is an extremely powerful tool as it holds 
the promise of fully saturating the causal genetic map of 
Mendelian disease. 
Disclosure: Nothing to disclose.
 
FW02-3
New opportunities of therapy in genetic 
neuropathies
D. Pareyson
Milan, Italy
There is still no effective drug treatment for Charcot-Marie-
Tooth (CMT) and related neuropathies. A Cochrane review 
of the six randomised controlled trials (RCTs) performed 
with ascorbic acid confirms that the drug is not effective in 
adults and children with CMT1A. Promising therapeutic 
approaches for different CMT types, based on cellular and 
animal model data, include: progesteron antagonists, high-
throughput screening for compounds down-regulating 
PMP22 expression, regulators of unfolded protein response 
and endoplasmic reticulum stress, Histon Deacetylase 6 
Inhibitors, modulators of neuregulin pathways, of GABA-B 
receptor and of P2X7 receptor. PXT3003, a fixed 
combination of low doses of baclofen, naltrexone 
hydrochloride and sorbitol, has been tested in CMT1A rats 
and in a phase II RCT in CMT1A patients; a phase III trial 
in under preparation. It is likely that other RCTs will start 
soon. L-serine supplementation appears a promising 
treatment for HSAN 1, associated with mutations in 
SPTCL1/2. Great advances are being achieved for 
hereditary amyloidosis associated with transthyretin gene 
mutations (TTR), for which orthotopic liver transplantation 
was the only available treatment until recently. TTR 
stabilizers (Tafamidis meglumine, for adult patients with 
stage 1 symptomatic polyneuropathy, and diflunisal as an 
off-label drug) showed encouraging results by significantly 
slowing disease progression. Oral doxycyclin plus 
tauroursodeoxycholic acid (TUDCA) is another promising 
approach aimed at both preventing and removing amyloid 
deposition. TTR gene silencing by means of either small 
interfering RNA or antisense oligonucleotides proved safe 
and effective in lowering TTR levels in phase II trials and 
phase III RCTs for both treatments are ongoing.
Disclosure: Nothing to disclose
Focused Workshop 3
Addressing quality of care for 
neurological patients
FW03-1
Optimising quality of care in epilepsy
E. Ben-Menachem
Gothenburg, Sweden
The key to improving quality care is to improve access to 
epilepsy centers and the facilities that they offer. It is 
important that when offering treatment for epilepsy the 
patient becomes a partner in care with access to as much 
information as possible about the disease and prognosis and 
possibilities of treatment. Quality of care means access to: 
Appropriate diagnostic capabilities delivered in a timely 
fashion. (1 or more EEG, MRT, possibly CSF when 
applicable, detailed history, physical exam, in difficult cases 
genetic testing, autoimmune analysis, if applicable). Lack 
of availability of video-EEG (vEEG)  facilities will decrease 
the possibility of optimal care as a diagnosis can be difficult 
unless seizures are evaluated with a combination of vEEG 
and ECG. Once a patient has been diagnosed, then treatment 
is offered. This can vary widely. The quality of care is 
greatly improved if the physician is well versed in the 
treatment possibilities for all types of epilepsy. It is usual to 
start with an antiseizure drug before going on to more 
advanced treatment options. If a patient does not become 
seizure free after 2-3 appropriate antiseizure drugs, then a 
new diagnostic evaluation should be done and other options 
such as epilepsy surgery considered. All along the support 
of a trained epilepsy nurse improves patient care by creating 
almost constant access to a professional when encountering 
social problems involved with epilepsy as well as a person 
whom to immediately report possible side effects that can 
be headed off before becoming serious. Access to a 
neuropsychologist and a social worker are important in 
epilepsy care enabling an assessment of cognitive deficits 
and an evaluation and treatment of psychological 
comorbidities. An interested psychiatrist is very important 
but many times not available. Together an epilepsy team 
will work together with the patient to provide the best care 
that is currently available. In Europe there are many such 
facilities, but unfortunately they are not evenly distributed 
so many patents will not have access to high quality care 
unless referred to centers specializing in epileptology. It 
should be the duty of all countries in Europe to strive to 
broaden the access of expert care to all regions in order to 
reach every patient. The social and economic gains of 
improve epilepsy care should make this mission of highest 
priority in every society.
Disclosure: Nothing to disclose.
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FW03-2
Quality standards of multiple sclerosis 
service
A. Chaudhuri
Romford, United Kingdom
Multiple Sclerosis (MS) is a life-long neurological disease 
with a high socio-economic burden. There is significant 
variability in timely diagnosis, treatment and care plan of 
MS patients. The key components of the proposed Quality 
Standards of MS service are:
1: ACCESS TO A DESIGNATED MS SERVICE: Patients 
must have access to a specialist neurological service, which 
should consist of, as a minimum, a consultant neurologist 
and a specialist nurse.
2: EARLY DIAGNOSIS OF MS: Patients are entitled to a 
timely diagnosis based on contemporary criteria with timely 
access to investigations (MRI and laboratory tests).
3: MANAGEMENT OF MS: There should be ease of 
access to multi-disciplinary specialist MS clinics for 
management of relapses and relapse-related symptoms. In 
addition to pharmacological therapy, a priority should be to 
improve symptom control and health related quality of life 
(HRQoL) using patient reported outcome measures 
(PROMs).
4: ACCESS TO APPROVED DISEASE MODIFYING 
THERAPIES: The treatment decision has to be 
individualised and take into account patient expectations 
and preferences while balancing potential benefits against 
risks of treatment appropriate for life-stage.
5: LONG TERM CARE FOR PATIENTS: The 
comprehensive care plan for MS patients should reach 
beyond specialist clinics into individual homes, workplaces 
and social life to deliver the best possible and full quality of 
life and identify community nursing, rehabilitative, 
psychological and social resources for continuation of 
support.
6: RESEARCH AWARENESS: Research should be an 
expected standard of clinical service and MS patients should 
be made aware of research projects for volunteerring and 
participation.  
Disclosure: Nothing to disclose
 
FW03-3
Health related quality of life in Parkinson's 
disease
M. Faber
Nijmegen, The Netherlands
Quality of life is a complex construct, and it is difficult to 
measure. Patients have a unique perspective on what good 
quality of care constitutes. Knowing this perspective not 
only empowers professionals to tailor their care to their 
patients’ individual needs, it also strengths the engagement 
between patients and their healthcare team. To better 
capture the patients’ perspectives, we developed and 
validated both a Dutch and a North-American Patient 
Centeredness Questionnaire for PD (PCQ-PD). Based on 
experiences of nearly 2,000 patients with Parkinson’s 
disease, ‘provision of tailored information’ and ‘emotional 
support’ could be identified as key elements in the care 
pathway that needed improvement. This example clearly 
demonstrates that patient experience scores can serve as a 
valid and powerful stepping stone for optimization of 
patient centred care delivery. Another way to encourage 
patient-centred care is to incorporate patient-reported 
outcomes (PROMs) into clinical settings. The PDQ-39, i.e. 
the standardized and disease-specific quality of life measure 
for Parkinson’s disease, is such a PROM. When incorporated 
into the health care visit, PROMs could fuel conversations 
between patients and providers that lead to shared decision 
making and promote the delivery of individualized care. 
Interviews with patients, neurologists and physiotherapists 
revealed that the impact highly depends on the presentation 
format and benchmarks used. In the Netherlands, a routine 
collection of the PCQ-PD and the PDQ-39 has recently 
been implemented. The standardized approach allows us to 
assess the care performance and its impact. During the 
workshop we will elaborate on the opportunities and 
challenges that come with this innovation. 
Disclosure: Nothing to disclose.
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Focused Workshop 4
Frontier applications in neurosonology
FW04-1
Magnetic resonance guided focused 
ultrasound for neurological disorders
I. Schlesinger
Haifa, Israel
Magnetic resonance guided focused ultrasound is a new 
technology that enables intracranial ablation without 
incisions. The ultrasound rays warm up the tissue through 
an intact skull creating the lesion with real-time MRI 
monitoring for localization and thermography. Intracranial 
tissue is warmed up gradually in a step wise fashion while 
the patient is awake. If adverse events occur the target can 
be repositioned before ablation. This technology is being 
used to treat patients with disabling tremor due to Essential 
tremor and Parkinson’s disease. In these patients, lesioning 
the ventral intermediate nucleus of the thalamus is effective 
in relieving tremor with infrequent long term adverse 
events. Ameliorating central neuropathic pain, reducing 
motor fluctuations in Parkinson's disease and disruption of 
the blood-brain barrier have anecdotally been reported and 
offer a glimpse at possible future applications.
Disclosure: Nothing to disclose
 
FW04-2
Ultrasound on the earth and in the orbit
Z. Garami
Houston, USA
Space adaptation syndrome and visual impairment with 
increased intracranial pressure (ICP) remain a puzzling 
problem of astronauts health and missions. These changes 
define the visual impairment/intracranial pressure (VIIP) 
syndrome. There are limited pre- and postflight measures to 
define the risk and even less inflight data is available. The 
goal of this study was to use multi-equipment ultrasound 
protocol simultaneously to measure intracranial and 
extracranial flow patterns (carotid duplex) before an 
astronauts mission to established baseline data that could 
provide important information about flow patterns during 
ICP with and without gravity. Simultaneous, multi-
equipment ultrasound testing could be helpful to study 
cerebral autoregulation and the connection between extra/
intracranial flow, as well as arterial/venous flow patterns 
with and without gravity in cerebrovascular syndromes. 
VIIP syndrome remains a puzzling problem of astronauts` 
health and it prevents the planning of longer missions to 
explore our boundaries in the universe. These observations 
are also relevant for medical conditions with ICP on Earth. 
TCD is already a useful tool in detecting vasospasm and 
occlusion in our every day practices but there is still room 
for improvement when dealing with unrecognized and 
underdetected ischemia and hypoperfusion after stroke, 
intracerebral or subarachnoid, and cerebellar hemorrhages. 
The danger of intracranial hypertension is frequently 
underestimated, especially in stroke patients. In many cases, 
ICP is not monitored, and it may cause severe secondary 
insults by unrecognized ICP elevation. Therefore, non 
invasive ICP assessment tools and methods developed for 
NASA could be a helpful tool for our patients, too.
Disclosure: Nothing to disclose.
 
FW04-3
The unstable carotid artery plaque
D. Russell
Oslo, Norway
Carotid plaque characteristics can help to identify those 
patients with a relatively higher risk for stroke and help 
select patients who may benefit from intervention over 
medical treatment alone. Echolucent plaques are thought to 
be more unstable than echo-rich plaques. Shear wave 
elastography provides information about plaque stiffness 
and a better correlation to histology compared to GSM 
assessments. 3D imaging has been used in volumetric 
measurements and the detection of plaque ulceration. 
Ultrasound contrast agents are helpful in detecting plaque 
surface irregularities and plaque neovascularization. Superb 
microvascular Imaging is a new ultrasound image technique 
(Toshiba Medical Systems) that allows the visualization of 
very small low-flow signals from small blood vessels in the 
plaque without the use of contrast agents. Symptomatic 
patients with microembolic signals, assessed by TCD, have 
a higher risk for developing ipsilateral stroke. MRI detects 
intraplaque hemorrhage, lipid-rich core, calcification, the 
fibrous cap and ulceration. Dynamic contrast-enhanced 
MRI allows assessment of plaque neovascularization. 
Patients with silent cerebral ischaemic events have a higher 
risk of future stroke. Positron emission tomography (PET) 
imaging assesses specific metabolic functions with tracers 
labelled with positron emitting radio-isotopes. PET with 
18Fludeoxyglucose can probe plaque inflammation in 
unstable plaques directly. Biomarkers have been shown to 
improve prediction independent of conventional risk factors 
and a recent study suggests that gamma-butyrobetaine 
(gamma-BB) and its precursor trimethyllysine (TML) may 
predict cardiovascular mortality. Application of plaque 
imaging in prospective studies will hopefully, in the near 
future, tell us how we can best guide treatment, especially 
in asymptomatic patients.
Disclosure: Nothing to disclose.
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Focused Workshop 5
Abnormal movements in sleep
FW05-1
Regulation of motor control during sleep
P.-H. Luppi
Lyons, France
Paradoxical sleep (PS) is characterised by muscle atonia 
induced by ponto-medullary-spinal pathways. It was first 
demonstrated that a pontine area recently named 
sublaterodorsal tegmental nucleus (SLD) contains the 
neurons inducing the muscle atonia of PS. Besides, it was 
shown that glycine induces the hyperpolarization of 
motoneurons during PS. We recently define in detail the 
network responsible of muscle atonia during PS combining 
Fos staining, retrograde tracing and immunohistochemistry 
or “in situ” hybridization of markers of cholinergic, 
glutamatergic, GABAergic and glycinergic neurons. We 
showed that glutamatergic neurons localized in the SLD 
triggered muscle atonia during PS by means of their 
descending projections to GABA/glycinergic neurons 
localized in the ventral medullary formation namely the 
ventral gigantocellular reticular nucleus (GiV). We further 
showed that these neurons project to the spinal cord and are 
activated during PS. To directly demonstrate the role of 
these glutamate and GABA/glycinergic neurons in PS 
atonia, we inactivated SLD glutamatergic or GiV GABA/
glycinergic transmission using transfection with AAVs of 
short hairpin RNA specific of the mRNAs of the vesicular 
glutamate 2 (vGLUT2) or GABA/glycine vesicular (vGAT) 
transporters. These animals display absence of atonia and 
large movements during PS confirming the role of the SLD 
glutamatergic neurons and the GABA/glycinergic neurons 
in the induction of muscle atonia during PS. In line with 
these results, we propose that REM sleep behavior disorder 
(RBD) is due to a specific degeneration of PS-on 
glutamatergic neurons localized in the SLD or the 
glycinergic/GABAergic premotoneurons localized in the 
GiV. Conversely, cataplexy in narcoleptic would be induced 
by a recruitment of the SLD neurons by a neuronal network 
regulating emotion.
Disclosure: Nothing to disclose.
 
FW05-2
Simple motor movements
A. Iranzo
Barcelona, Spain
Sleep is a physiological state characterized by reduced 
bodily movement. However, healthy people, particularly 
young persons, may display non pathological simple 
manifestations like facial grimaces, minor jerks, and 
isolated behaviors such as kicking, slapping and sobbing. 
These “normal” behaviors may occur during the transition 
from wakefulness to sleep (e.g., hypnic starts), nonREM 
sleep (e.g. sleep talking) and REM sleep (e.g., head 
myoclonus, repetitive movements of the feet and hands). In 
addition, the following pathological conditions may present 
with simple motor events. REM sleep behavior disorder. In 
addition to complex behaviors like punching or jumping out 
of bed, patients present simple manifestations such as jerks, 
grimaces, kissing, laughing or waving arms. NONREM 
sleep parasomnias. In addition to complex behaviors 
occurring in sleepwalking and night terrors patients may 
present confusional arousals where they simply open their 
eyes, look around, mutter and sit up in bed. Nocturnal 
frontal lobe epilepsy. Besides dystonic postures and 
wandering patients may display minor events called 
paroxysmal arousals consisting in body jerks and raising the 
head and sit on bed. Hypnagogic foot tremor. Series of 
rhythmic and fast movements of the whole foot during light 
sleep. Periodic leg movements in sleep. These movements 
may be minor, asymptomatic, and only involving the foot 
and ankle. Restless legs syndrome. Patients may show foot 
taping to alleviate their unpleasant leg sensations during 
wakefulness. Cataplexy. Some cataleptic events may be 
minor only involving the head or the knees during few 
seconds.  
Disclosure: Nothing to disclose.
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FW05-3
Complex motor movements
R. Khatami
Barmelweid, Switzerland
Motor symptoms during sleep comprise a spectrum of 
paroxysmal phenomena that lead to sleep disruption, sleep 
fragmentation and eventually contribute to excessive 
daytime sleepiness. According to the International 
Classification of Sleep Disorders (ICSD-III) paroxysmal 
motor phenomena during sleep include parasomnias, sleep-
related movement disorders, epilepsies and isolated 
symptoms. This workshop aims at characterizing the 
clinical features, etiology, electrophysiological features and 
treatment of complex motor behavior occurring during 
NREM-sleep, REM sleep or sleep state transitions. Starting 
from video presentations the semiology of typical and 
atypical features will be introduced. Complex motor 
symptoms may present as repetitive movements or semi-
purposeful often stereotyped behavior. Specific forms 
include violent behaviors leading to self-injuries or harmful 
behavior directed to others. Clinical and electrophysiological 
features will be added to further characterize the underlying 
pathophysiology. The workshop will show that complex 
motor behaviors are not necessarily a unitary phenomenona, 
but should rather be considered as the manifestation of a 
variety of different diseases, as exemplified by cases of 
arousal disorders, nocturnal frontal lobe epilepsy and 
psychiatric disorders. Thus, careful examination and 
extended diagnostic workup is needed for proper diagnosis 
of underlying disease and adequate treatment. 
Disclosure: Nothing to disclose.
 
Focused Workshop 6
New concepts about language 
processing in the brain
FW06-1
The dual-loop model and aphasia
C. Weiller
Freiburg, Germany
A dual-loop model for the processing of language in the 
brain was proposed early in history and has also formed the 
basis for many neuropsychological models. These models 
incorporate a (direct) route for sensorimotor mapping and a 
(indirect) route for “semantic“ processing. Dual-loop 
models also emerged in the field of visual processing, motor 
control, or spatial attention. Thus, a general dual-loop 
system emerges as a framework for the interpretation of 
cognition in human brains independent of the modality. 
Modern imaging techniques like Diffusion-Tensor-Imaging 
(DTI) based fibre tracking identified several long human 
association tracts for ventral and dorsal pathways. The 
extreme capsule (EmC)/IFOF and uncinate fascicle (UF) 
are part of the ventral system, and the superior longitudinal 
fasciculi (SLF II, III) and the arcuate fasciculus (AF) are all 
dorsal pathways. This talk reviews language processing in 
the brain in the context of a domain general dual-loop 
system on basis of imaging studies in normal subjects and 
patients with aphasia. In short: speech production is a dorsal 
stream task, while comprehension requires the ventral 
stream. At the acute stage, Wernicke’s aphasia (posterior 
STG/MTG) and Broca’s aphasia (mainly inferior frontal 
gyrus (IFG) map to defined brain regions affecting both 
streams, thus explaining phonological (d) and semantic (v) 
paraphasias and comprehension problems (v) in Wernicke’s 
and agrammatism in Broca’s aphasia, as the IFG comprises 
the necessary interaction node for the two stream to extract 
structure from a sequence, a prerequisite for syntax 
processing.
Disclosure: Nothing to disclose.
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FW06-2
The impact of bilingualism on cognitive 
functions across the lifespan and in brain 
diseases
T. Bak
Edinburgh, United Kingdom
The last decades have witnessed fundamental changes in 
our understanding of both brain and language. In 
neurosciences, the static localisationist view of a 1:1 
correspondence between circumscribed brain areas and 
specific cognitive functions gave way to a dynamic 
interaction of multiple networks, in which the same function 
can be distributed among many areas and the same area can 
be part of different networks. In parallel, the concept of 
language as an autonomous, “informationally encapsulated” 
module has been superseded by the notion of widely 
distributed language-related brain networks, going well 
beyond the traditional language areas and interacting with 
other aspects of cognition. These advances in the 
neuroscience of language have been of particular importance 
for our understanding of bilingualism. Firstly, we came to 
realise that different languages of a multilingual person 
cannot be reduced to static representations in isolated brain 
areas but are subject to parallel activation, inhibition, 
switching and monitoring within the same brain networks. 
Secondly, the tension between this parallel activation and a 
selective output necessary for successful communication 
constitutes a permanent training for frontal-executive 
functions. Accordingly, the cognitive effects of bilingualism 
transcend language itself, leading to a better performance 
on many executive tasks, particularly those requiring 
inhibition and switching. This mechanism offers an 
explanation for a number of recent empirical findings, in 
which bilinguals were show to be more resistant to cognitive 
ageing than monolinguals, develop dementia ca. 4 years 
later and show a significantly better cognitive recovery after 
stroke.
Disclosure: Nothing to disclose. 
FW06-3
The writing brain
J.-F. Démonet
Lausanne, Switzerland
A vast neural network underpins the functional processing 
by which the orthographic signal is transformed to motor 
output; at the neocortical level, these neural territories 
encompass the upper lateral premotor and parietal cortex. 
The premotor component, first described by Exner, likely 
plays a role of buffer interfacing orthographic and 
allographic components of handwriting. The involvement 
of the premotor cortex in the non-dominant hemisphere and 
of transcallosal connections has yet to be specified as well 
as the role of the superior parietal cortex. The neural 
correlates of central orthographic processes in handwriting 
involve “Broca’s area and the posterior temporal cortex in 
which we observed "dual route" effects, referring to dorsal/
ventral processing, respectively involved in sublexical and 
lexical semantic aspects of orthographic coding. For a 
review: Planton et al. The “handwriting brain”: a meta-
analysis of neuroimaging studies of motor versus 
orthographic processes Cortex 2013 49: 2772-2787
Disclosure: Nothing to disclose
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Focused Workshop 7
Stem cell therapies for the treatment of 
neurological diseases
FW07-1
Adult Stem Cells for the treatment of 
multiple sclerosis
A. Uccelli
Genova, Italy
Adult stem cell treatments are a promising strategy for 
curing multiple sclerosis (MS). Results obtained from 
pioneer clinical studies of transplantation of autologous 
hematopoietic stem cells (AHSC) have demonstrated that 
this procedure is highly effective in severe forms of MS 
based on the abrogation of autoreactive clones and reset of 
the immune system. However, this procedure associates 
with consistent risks of severe and rarely lethal adverse 
events. Neural precursor cells (NPC) exert neuroprotective 
and immunomodulatory effects fostering tissue repair in 
mice with experimental autoimmune encephalomyelitis 
(EAE). Similar encouraging results have been obtained in 
EAE using induced pluripotent stem cells (iPS). However, 
safety and feasibility issues concerning their transplantation 
in MS are yet to be addressed. Mesenchymal stem cells 
(MSC) isolated from the bone marrow or adipose tissues 
display a significant therapeutic plasticity as reflected by 
their ability to enhance tissue repair and influence the 
immune response leading to significant amelioration of 
EAE. Thus, small clinical trials in MS subjects have 
demonstrated that MSC administration is safe and provided 
an early signal of clinical effectiveness. A large phase II 
multicenter clinical trial is on-going with the aim of 
demonstrating safety and efficacy of  MSC. Overall, current 
experimental evidence suggests that clinical exploitation of 
adult stem cells for MS may lead to novel strategies aimed 
at blocking uncontrolled inflammation, protecting neurons 
and promoting repair, but not at restoring deranged neural 
network responsible for irreversible disability.
Disclosure: Nothing to disclose.
 
FW07-2
Stem Cells in muscle diseases
Y. Torrente
Milan, Italy
Cell therapy is one promising approach to correct genetic 
diseases by contributing to tissue regeneration; stem cells 
can be isolated from a healthy donor or, when possible from 
the same patient. In the first case cells will be transplanted 
under a regime of immune suppression while in the second 
case, cells will have to be genetically corrected before 
transplantation in the same patient from which they were 
derived. The overall objective of our work is the validation 
of a clinical treatment for patients affected by Duchenne 
muscular dystrophy. The project does the groundwork for a 
phase I/II clinical trial consisting of an intramuscular 
transplantation of autologous CD133+ stem cells after their 
engineering through a lentiviral vector. The trial is oriented 
to DMD boys as Duchenne muscular dystrophy is a 
X-linked disorder characterized by a mutation in dystrophin 
gene. Efficacy and possible adverse effects have to be 
evaluated to test whether this approach may represent a first 
step towards an efficacious therapy for muscular dystrophy. 
Our previous works indicated that CD133+ stem cells, a 
recently identified population of progenitor cells, produce 
functional improvement upon intra-arterial injection in a 
mouse model of muscular dystrophy. It thus could be 
possible to focus on this type of stem cell for autologous 
transplantation in DMD animal models. Recently 
transplantation of engineered dystrophic canine muscle-
derived CD133+ cells gave promising results in Golden 
Retriever dystrophic dogs, the most reliable animal model 
that shows a form of dystrophy very similar to and even 
more severe than DMD. 
Disclosure: Nothing to disclose.
 
FW07-3
Cell transplantation for stroke
S.I. Savitz
Houston, USA
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Focused Workshop 8
MDS-ES/EAN: Tics and Tourette 
syndrome - consensus and 
controversies
FW08-1
Challenges in diagnosing tics, Tourette's 
and comorbidities
K. von Plessen
Bergen, Norway
Diagnostic categories within Tic disorders (inclusive 
Tourette syndrome) include transient, as well as more 
chronic conditions. Tic disorders are characterized by the 
presence of tics, which are involuntary contractions of 
muscles or vocal expressions, but may also compromise 
more complex behaviors. Tourette syndrome is a relatively 
frequent and complex neuropsychiatric disease that requires 
interdisciplinary collaboration between medical 
professionals, especially because the presence of comorbid 
conditions is rather the rule than the exception. Comorbidity 
with Attention-Deficit/Hyperactivity Disorder and 
obsessive-compulsive disorder is frequent and may pose 
several diagnostic challenges in young people. A recent 
European guideline thus recommends the use of a structured 
diagnostic instrument to screen for other psychiatric 
diagnoses and specific instruments allowing a dimensional 
mapping tics and possible other co-morbid conditions. 
Besides the most frequent instruments for diagnostic 
mapping of psychopathology, also current theories and 
concepts regarding the neurobiological/neuropsychological 
basis and subsequent adaptation to tics will be presented.
Disclosure: Nothing to disclose.
 
FW08-2
Tics and Tourette syndrome - Movement 
disorders or behavioural conditions?
A.E. Cavanna
Birmingham, United Kingdom
Patients with Tourette syndrome (TS) show  a wide range of 
clinical presentations, characterised by different levels of 
severity and complexity. The concept of ‘TS spectrum’ 
encompasses conditions characterised by tics only (‘pure 
TS’), tics and complex symptoms such as self-injurious 
behaviours (‘full-blown TS’), tics and co-morbid 
behavioural problems such as obsessive-compulsive 
disorder and attention-deficit and hyperactivity disorder 
(‘TS-plus’). Over the last decade, clinical studies using 
principal component factor analysis and hierarchical cluster 
analysis have suggested the existence of discrete phenotypes 
within the TS spectrum. These findings have important 
implications for the understanding of genotype-phenotype 
correlations, as well as impact on patients’ health-related 
quality of life and choice of treatment interventions.
Disclosure: Nothing to disclose.
 
FW08-3
Treatment of tics and Tourette syndrome - 
Cannabis, deep brain stimulation and 
beyond
K. Müller-Vahl
Hanover, Germany
Tourette syndrome (TS) is a childhood onset 
neurodevelopmental disorder characterized by multiple 
motor and one or more vocal tics. The majority of patients 
suffers, in addition, from psychiatric comorbidities such as 
attention deficit hyperactivity disorder (ADHD), obsessive-
compulsive disorder (OCD), depression, anxiety, and self-
injurious behavior. Tics most typically start at age 6-8 years, 
fluctuate spontaneously in the course of the disease, are 
influenced by different environmental factors, and improve 
spontaneously in adolescence and young adulthood in the 
majority of patients. Treatment of patients with TS depends 
not only on severity of tics, but also the presence and 
severity of comorbidities. Since it is well known that TS can 
cause significant impairment in patient’s quality of life, in 
addition, overall social impairment has to be taken into 
consideration. First-line treatment for tics includes either 
cognitive behavioral treatment (using habit reversal training 
or exposure and response prevention training) or 
pharmacotherapy (using dopamine receptor blocking drugs 
including aripiprazole, tiapride (in children), sulpiride, and 
risperidone). However, in most European countries only 
haloperidol is formally approved for the treatment of tics. 
Since these substances are not effective in all patients and 
often associated with significant adverse effects, several 
other treatment alternatives have we suggested. There is 
increasing evidence that cannabis-based medication might 
be such an alternative treatment option that improves not 
only tics, but also psychiatric symptoms such as ADHD and 
OCD. In adult, severely affected, and otherwise treatment 
resistant patients surgical treatment with deep brain 
stimulation should be taken into consideration. 
Disclosure: Nothing to disclose.
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Focused Workshop 9
Focal dementias
FW09-1
The parietal lobes
J.M. Schott
London, United Kingdom
Building on the theme of this focussed workshop, this 
session will present an overview of the cortical dementias 
that have a particular prediliction for the parietal lobes, 
using posterior cortical atrophy - sometimes termed the 
visual variant of Alzheimer's disease - and corticobasal 
syndrome as the exemplar disorders. Starting with an 
overview of the anatomy and normal cognitive functions 
subserved by the parietal lobes, aspects of the history, 
examination and neuropsychology associated with dominant 
and non-dominant parietal lobe dysfunction will be 
illlustrated using videos. This will be followed by a 
discussion of the relevant investigations (imaging and CSF) 
and the underlying pathology of the neurodegenerative 
disorders leading to parietal lobe dysfunction. 
Disclosure: I acknowledge the support of the NIHR Queen 
Square Dementia BRU, the NIHR UCL/H Biomedical 
Research Centre, Wolfson Foundation, EPSRC, MRC, 
ARUK, and EU Horizon 2020. I have received research 
funding from AVID Radiopharmaceuticals, have consulted 
for Roche Pharmaceuticals and Eli Lilly, and serve on a 
Data Safety Monitoring Committee for Axon Neuroscience 
SE 
 
FW09-2
The temporal lobes
S.F. Cappa
Milan, Italy
Focal degeneration of the temporal lobes is the hallmark of 
the semantic variant of frontotemporal lobar degeneration. 
This condition, originally described by Arnold Pick, is most 
often associated with asymmetric involvement, prevalent on 
the left side, resulting in a clinical picture of progressive 
semantic dysfunction characterized by a level of selectivity 
and a severity of progression, which cannot be observed in 
any other neurological disease. The study of patients 
affected by this condition, most commonly due to TDP 43 
proteinopathy, has provided unique insights into the 
neurology of meaning representation. The less common 
presentation with greater right sided involvement is 
characterized by a different symptom complex, in which 
disorders of high order visual processing are often 
associated with prominent behavioural manifestations. The 
neuropsychological study of the latter cases is providing 
complementary insights into the neurology of non-verbal 
semantics and of social cognitive abilities. Atypical 
presentations of Alzheimer’s disease (AD) can also affect 
the temporal lobes focally for a prolonged period of time. 
Also in this case the asymmetry of involvement is a crucial 
determinant of the neuropsychological features, in term of 
aphasic (left sided) or visuospatial (right sided) 
presentations. A selective involvement of the medial 
temporal lobe is the hallmark of the puzzling condition of 
hippocampal sclerosis. Often diagnosed as AD in the past, 
this frequent cause of memory impairment in the elderly 
population can be associated with a number of degenerative 
and non degenerative conditions, including TDP 43 
pathology.
Disclosure: Nothing to disclose
FW09-3
The frontal lobes
R. Ossenkoppele
Amsterdam, The Netherlands
The frontal lobes play an important role in modulating 
human behavior, cognitive processes and motor function. 
This presentation focuses on how distinct neurodegenerative 
conditions (e.g. behavioral variant frontotemporal dementia, 
non-fluent variant primary progressive aphasia and 
progressive supranuclear palsy) affect the frontal lobes. 
More specifically, I will address the clinical syndromes, 
neuroimaging features and neuropathological changes 
associated with these diseases. Finally, I will present our 
studies on the behavioral/dysexecutive variant of 
Alzheimer’s disease.
Disclosure: Nothing to disclose.
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Focused Workshop 10
MDS-ES/EAN: Biomarkers for 
Parkinson's disease
FW10-1
The need for better biological markers for 
PD
W. Poewe
Innsbruck, Austria
Slowing of disease progression remains the single most 
important unmet need in the treatment of Parkinson’s 
Disease (PD). However, numerous clinical trials over the 
past 20 years failed or produced inconclusive results. 
Reasons for such failures include difficulties in choosing 
clinical endpoints and the lack of reliable biomarkers 
sensitive to disease progression. In addition, target 
populations for neuroprotective or disease-modifying trials 
have been those with early, clinically established PD. 
Recent research has provided substantial evidence that the 
pathology underlying PD likely begins years before the first 
manifestation of classical motor signs of PD. It is therefore 
conceivable that disease-modifying or neuroprotective 
interventions targeting the earliest phases of PD might offer 
greater potential for disease modification as compared to 
later stages. Idiopathic REM-sleep behavior disorder, 
hyposmia, depression, constipation have all been associated 
with an increased risk to later develop classical motor PD 
and might represent “pre-motor” stages of the illness. 
Recently a task force of the International Parkinson’s 
Disease and Movement Disorder Society (MDS) has 
proposed operational research criteria for the definition of 
prodromal PD. Nevertheless validated biomarkers are 
needed to enhance sensitivity and specificity of such 
criteria. The same holds true for early diagnosis as well as 
measuring disease progression.
Disclosure: Nothing to disclose
 
FW10-2
Alpha-Synuclein: a new evidence?
W. Meissner
Bordeaux, France
The discovery of alpha-synuclein as the main constituent of 
Lewy bodies in surviving dopamine neurons in Parkinson’s 
disease (PD) has stimulated research to determine the 
usefulness of this protein as biomarker for the diagnosis and 
prognosis of PD. In its physiological form, alpha-synuclein 
forms an unfolded monomer with a role in vesicle trafficking 
and recycling. The protein can undergo a multitude of 
posttranslational modifications including truncation and 
phosphorylation, and forms aggregates under particular 
conditions. Oligomers are currently believed to be the most 
toxic aggregates and seem to have a major role in the 
underlying neurodegenerative process. Several studies have 
reported decreased levels of total alpha-synuclein and 
increased concentrations of oligomers in the cerebro-spinal 
fluid (CSF) of PD patients compared to healthy controls. 
Total alpha-synuclein CSF levels were also decreased in 
patients with multiple system atrophy, suggesting that this 
marker may not be useful for the distinction between 
synucleinopathies. Preliminary results of prospective 
studies further suggest that concentrations of total alpha-
synuclein are not changing over time and are not correlated 
with disease severity. More recent studies have looked at 
alpha-synuclein levels in more accessible fluids (e.g. blood 
and saliva) and tissues (e.g. skin, salivary glands and colon 
biopsies). In this line, preliminary evidence suggests 
increased plasma concentrations of exosomal alpha-
synuclein. These results, together with encouraging findings 
in tissues, warrant replication and further investigation. The 
presentation will discuss recent progress and promising 
future avenues for the development of alpha-synuclein as 
biomarker in PD and synucleinopathies.
Disclosure: Nothing to disclose
FW10-3
Imaging Markers: MRI
U. Sabatini
Rome, Italy
When magnetic resonance imaging (MRI) was initially 
introduced in clinical practice, conventional neuroimaging 
techniques had a marginal role in the diagnosis of 
Parkinson’s disease (PD). The increasing prevalence of PD, 
partly as a consequence of population ageing, the 
introduction of experimental therapeutic strategies, and 
technological advances in MRI have stimulated the 
development of MRI techniques with a potential for greater 
sensitivity and specificity for early diagnosis and the 
quantification of the pathological process. With the 
introduction of higher field magnets and novel imaging 
sequences, microstructural, metabolic and functional data 
is, as never before, contributing to the search for reliable 
biomarkers of disease progression in PD. Results from 
existing studies have suggested several MRI-based 
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measures as potential biomarkers of PD pathology, albeit 
none of them has yet been identified as a clear winner. 
These studies converge towards the notion that a single 
MRI modality cannot be sufficient to characterise the 
complex pathological mechanisms underlying PD. In fact, 
multimodal MRI sequences are able to capture tissue 
characteristics at different scales: macroscopic structure can 
be assessed through volumetric T1-weighted, 
microstructural alterations can be detected through 
diffusion-weighted, iron deposition in specific brain 
structure can be quantified through R2* imaging. For this 
reason, the integration of multimodal MRI indexes is 
crucial, since they probably carry complementary 
information regarding the biological process of interest. 
Datasets in a large cohorts of accurately selected patients, 
acquired at multiple sites, will grant the opportunity of 
testing multimodal MRI techniques over large amounts of 
clinical, neuroimaging and genetic data.
Disclosure: Nothing to disclose.
 
FW10-4
Imaging Markers: PET/SPECT
P. Remy
Créteil, France
The use of dopaminergic presynaptic ligands such as 
18F-DOPA (PET) or cocaine analogues (PET/SPECT) has 
been used for years to measure the progression of 
neurodegenerative process in Parkinson’s disease (PD). 
Although several studies have used PET or SPECT to 
investigate neuroprotective potentiality of several 
treatments, to date results have been either negative or 
highly debated. One major issue is to obtain a clinical 
benefit in patients whose disease has been slowed according 
to imaging data. Another marker which has been more 
recently used is the measure of endogenous synaptic 
dopamine release. Using an 11C-Raclopride displacement 
method it is possible to demonstrate enhanced dopamine 
availability in the striatum induced by cell or gene therapy. 
Eventually, new processes are now investigated to identify 
alternative markers of PD, such as inflammatory process, 
using ligand of the TSPO which reveals glial activation. In 
addition, a ligand of a-synuclein would be considered as a 
dramatic improvement in our ability to measure PD 
degenerative process and to evaluate immunotherapy 
against a-synuclein deposition which is already investigated 
in patients.
Disclosure: Nothing to disclose.
Focused Workshop 12
Impaired hand function after stroke 
and peripheral nerve injury: 
consequences for treatment
 
FW12-1
Treatment of hand function after 
peripheral nerve injury
J. Valls-Solé
Barcelona, Spain
Nerve growth after injury in peripheral nerves is a 
physiological process. It occurs naturally after the lesion 
and, although it can be promoted by some drugs such as 
growth factors, it will occur even in rather adverse situations 
if the nerve has not lost its continuity. There are many 
problems with reinnervation: There is a critical window of 
time in which regeneration must occur for optimal recovery 
to be achieved. If distal Schwann cells lack axonal contact 
for a long time, they degenerate, reduce secretion of growth 
factors, disappear from the bands of Büngner and stop 
replication, leading to irreversible changes detrimental for 
functional recovery. It is nowadays impossible to guide the 
regenerating axons up to the target that they had before the 
lesion. If nerve regeneration occurs, reinnervating axons 
may end up innervating a structure different from the one 
they were innervating before the injury. There are changes 
at motoneuronal level that make the motoneurons 
hyperexcitable and respond to inputs from many sources to 
which they did not respond before the injury. Finally, axon 
growing means also axonal branching. This provides 
electrophysiologic studies but also more possibilities of 
innervation errors and inefficacy of the reinnervated targets. 
The recovery of hand function depends on all these factors, 
which are conditioning the rehabilitation progress.
Disclosure: Nothing to disclose.
 
FW12-2
Normal and impaired neural coupling of 
cooperative hand movements
V. Dietz
Zurich, Switzerland
In recent years it has become evident that, in a number of 
functional movements, synergistically acting limbs become 
task-specifically linked by a soft-wired ‘neural coupling’ 
mechanism (e.g. the legs during balancing, the arms and 
legs during gait and both arms during cooperative hand 
movements). Experimentally this mechanism becomes 
elucidated by reflex responses as a marker for a neural 
coupling. This reflected by the task-specific appearance of 
reflex EMG responses to non-noxious nerve stimulation, 
not only in muscles of the stimulated limb, but also, with 
same long latency, in muscles of meaningful coupled 
(contralateral) limb(s). After a stroke, nerve stimulation of 
the unaffected limb during such cooperative tasks is 
© 2016 European Journal of Neurology, 23 (Suppl. ), 880–8992
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followed by EMG responses in muscles of the (contralateral) 
coupled affected limb, i.e. unaffected motor centres 
influence synergistically acting movements of the paretic 
limb. In contrast, following stimulation of the affected limb, 
no contralateral responses appear due to defective 
processing of afferent input. As a consequence, it may be 
therapeutically possible to strengthen the influence of 
unaffected motor centres on the performance of affected 
limb movements through training of cooperative limb 
movements required during activities of daily living.
 
Disclosure: Nothing to disclose
 
FW12-3
Bilateral hand movement training after 
stroke: what is the benefit?
C. Renner
Leipzig, Germany
Introduction: Different training strategies have been tested 
in neurorehabilitation of motor function. Examples include 
constraint-induced movement therapy (CIMT) and bilateral 
arm training (BAT), They are based on divergent hypotheses 
of poststroke reorganization. CIMT promotes activation of 
the ipsilesional hemisphere counteracting contralesional 
activation, while BAT involves bihemispheric activation. 
Yet severely impaired stroke patients unable to move their 
hands are unable to perform CIMT.
Methods: 60 patients with a severe arm paresis were 
recruited for this randomized single-blinded study and 
stratified according to lesion location. The bilateral arm 
training entailed a repetitive training on an “arm-cycle” 
followed by synchronized bilateral repetitive distal hand 
training. The unilateral arm training was identical but 
performed by the paretic limb only. Both trainings were 
administered twice daily over six weeks and incorporated 
shaping elements. Main outcome measures included the 
FMA and biomechanical parameters measuring isometric 
force and rate of force generation.
Results: Both trainings lead to a significant improvement 
of the FMA and all biomechanical parameters. Patients with 
pure subcortical stroke, but not patients with cortical 
involvement of stroke, showed a significantly greater 
improvement following the bilateral training in FMA 
(p=0.03) and hand extension (p=0.02) compared to 
unilateral training. 
Conclusion: Bilateral arm training followed by repetitive 
bilateral hand training leads to greater improvements in 
motor control and force of the severely paretic upper limb 
compared to the unilateral training after pure subcortical 
stroke lesions. These findings may assist in planning 
different therapeutic regiments in the context of motor 
impairment severity and lesion location.
Disclosure: Nothing to disclose
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Sleep and cognition
FW13-1
Sleep and cognition
P. Maquet
Liege, Belgium
Human performance results from an interaction between 
circadian rhythmicity and homeostatic sleep pressure 
accumulated during wakefulness. Whether and how this 
interaction is represented at the level of regional brain 
responses has not been established. We quantified changes 
in brain responses to 2 cognitive  tasks during 13 functional 
magnetic resonance imaging (fMRI) sessions scheduled 
across the circadian cycle during 42h of wakefulness in 33 
healthy participants. The temporal profile of cortical 
responses shows a significant circadian rhythmicity, the 
phase of which varies across brain regions. Cortical 
responses also significantly decrease with accrued sleep 
debt. By contrast, subcortical areas exhibit primarily a 
circadian modulation, which closely follows the melatonin 
profile. These results demonstrate a local modulation of 
brain responses by both circadian rhythmicity and sleep 
pressure. These results have important bearing on our 
understanding of sleepiness-related traffic and work 
accidents, insomnia and rehabilitation programs.
Disclosure: Nothing to disclose
 
FW13-2
Sleep and emotion
V. Sterpenich
Geneva, Switzerland
Recent research has demonstrated that freshly encoded 
memory traces are replayed during sleep. This mechanism 
allow information to be integrated into an existing network 
of representations. During wakefulness, the brain is 
bombarded with large amounts of information. Thus, to 
better understand how replay during sleep contributes to 
memory processes, we need to determine what type of 
information is prioritized for subsequent replay during 
sleep. We hypothesized that information with an affective 
value, which might require long-term behavioral changes, 
would benefit from offline reprocessing during sleep. Thus, 
memories of emotionally relevant experiences may have a 
higher probability of being reprocessed during sleep. Using 
simultaneous EEG-fMRI recordings, we measured brain 
activity while healthy participants played alternating blocks 
of two distinct games, one of which they would eventually 
win. We also measured brain activity during different sleeps 
stages. Using a neural decoding approach we found that the 
pattern of brain activity associated with the rewarded game 
occurs spontaneously during deep sleep and more frequently 
than the non-rewarded game. In a second experiment, we 
artificially reactivated emotional memory traces during 
sleep using auditory cues in patients with intracranial EEG 
recordings. We observed that the cues associated with 
positive events would elicit distinct iEEG responses during 
sleep in brain regions involved in emotion and memory. 
Taken together, these findings suggest a general mechanism 
whereby the brain selectively consolidates memories with a 
high value for survival. The replay of relevant memories 
occurs during a physiological state, i.e. sleep, that is highly 
favorable for neural plasticity.
Disclosure: Nothing to disclose
 
FW13-3
Sleep and dementia
S. Overeem
Heeze, The Netherlands
Alzheimer's disease (AD) is the most common form of 
progressive dementia. It has been known for a long time 
that AD patients frequently suffer from sleep disturbances 
as well as circadian rhythm disorders. In recent years 
however, evidence is accumulating that suggests a 
bidirectional relationship between AD and sleep, i.e. sleep 
disturbances may be a risk factor to develop AD. Several 
epidemiological studies have shown that sleep restriction 
increases the risk of cognitive impairment. Experiments in 
mice showed that sleep deprivation leads to a marked 
increase in amyloid beta accumulation. Most likely, sleep 
contributes to the clearance of metabolites such as amyloid 
beta from the brain. More recently, studies have shown 
comparable mechanisms in humans. For example, sleep 
deprivation lead to an increase in cerebrospinal fluid 
amyloid beta levels in healthy subjects. Besides a link 
between sleep and amyloid dynamics, other factors may be 
at play. For example, melatonin may have antioxydant, 
neuroprotective as well as anti-amyloidogenic effects.
Disclosure: Nothing to disclose
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Focused Workshop 14
Gut microbiota, immunology and 
neurological diseases
FW14-1
Microbiota and the gut-brain axis
P. Lepage
Micalis Institute, INRA, AgroParisTech, Université Paris-
Saclay, Jouy-en-Josas, France
Modifications in the bacterial composition and diversity of 
the human gut microbiota (microbial dysbiosis) have been 
associated with digestive tract dysfunctions such as 
inflammatory bowel diseases. More strikingly, microbial 
dysbiosis may be associated with pathologies at distance 
from the intestine and strong evidence, from both human 
studies and animal models, links intestinal microbiota 
dysbiosis with metabolic disorders, such as obesity. More 
recently, associations between microbial imbalances in the 
gut and neurologic and behavioural disorders have been 
described in animal models. While some gut microbes have 
the capability to produce neuromediators that may exert 
effects in the brain, only sparse data are available in humans 
and most of them remain highly descriptive. Yet, the 
possible involvement of the ‘microbiota-gut-brain’ axis in 
the development of disorders ranging from autism, multiple 
sclerosis or depression is currently being investigated. The 
development of meta-omic technologies that give insight 
into the functions and potential effect of the non-cultured 
intestinal bacteria on the host health will surely help 
understanding how modifications in this finely tuned 
ecosystem lead to these pathological processes. This may 
finally lead to the development of new therapeutical 
approaches to treat and ameliorate these neurological 
diseases.
Disclosure: Nothing to disclose
 
FW14-2
Microbiota and CNS autoimmunity 
(Multiple Sclerosis)
G. Krishnamoorthy
Martinsried, Germany
Autoimmunity results from a combined influence of genetic 
and environmental factors. Emerging evidence in the 
experimental models of autoimmunity suggests an 
important contribution of gut microbiota in the disease 
development. In this presentation, i will present evidence 
for the role of gut microbiota in mouse models of Multiple 
Sclerosis, an autoimmune disease of the central nervous 
system with the special emphasis on how to modulate gut 
microbiota for therapeutic benefit. 
Disclosure: Nothing to disclose
 
FW14-3
Gut microbiome: a key regulator of 
neurodevelopment and behaviour
J.F. Cryan
Cork, Ireland
The brain-gut-microbiota axis is emerging as a research 
area of increasing interest for those investigating the 
biological and physiological basis of neurodevelopmental, 
age-related and neurodegenerative disorders. The routes of 
communication between the gut and brain include the vagus 
nerve, the immune system, tryptophan metabolism, via the 
enteric nervous system or by way of microbial metabolites 
such as short chain fatty acids. Studies in animal models 
have shown that the development of an appropriate stress 
response is dependent on the microbiota. Developmentally, 
a variety of factors can impact the microbiota in early life 
including mode of birth delivery, antibiotic exposure, mode 
of nutritional provision, infection, stress as well as host 
genetics. At the other extreme of life, individuals who age 
with considerable ill health tend to show narrowing in 
microbial diversity and a proinflammatory phenotype. 
Stress can significantly impact the microbiota-gut-brain 
axis at all stages across the lifespan. We have recently 
shown that fundamental brain processes important for 
neurological diseases are regulated by the microbiome. 
These include adult hippocampal neurogenesis and 
hippocampal expression of BDNF. In the amygdala, germ 
free animals have increased volume, spine density and 
morphology, whereas in the prefrontal cortex myelination 
and myelin-related gene expression is dependent on the 
microbiome. It has also recently been shown that microglia 
activation and blood brain barrier integrity are also 
microbiome-dependent processes. Further studies will 
focus on understanding the mechanisms underlying such 
brain effects. Together these data offer the intriguing 
possibility of therapeutically targeting specific brain 
processes via the gut microbiome.
Disclosure: Nothing to disclose.
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Focused Workshop 15
Exome sequencing goes bedside: new 
genes in neurological disorders
FW15-1
Cerebellar ataxias: exome sequencing 
unravels novel genes, false friends and 
clinical hints for bedside
M. Synofzik1, F. Harmuth2, S. Züchner3, L. Schöls1,  
P. Bauer1, R. Schüle1
1Tübingen, Germany, 2Institute of Medical Genetics and 
Applied Genomics, Tübingen, Germany, 3Miami, USA
Cerebellar ataxias present a heterogeneous group of 
degenerative and metabolic diseases. Based on the advances 
of next-generation sequencing (NGS) techniques such as 
panel, whole exome sequencing (WES) and whole genome 
sequencing (WGS), the number of newly identified genetic 
causes of ataxias is rapidly increasing, with >120 ataxia-
associated genes now being identified. This talk will 
demonstrate that these genetic advances provide 
unprecedented options to diagnose previously unsolved 
ataxia patients, to define the genetic basis of many rare and 
complex ataxia disorders, and to pave the way towards 
molecular pathways and treatments. In step one, a state-of-
the art overview on NGS findings in ataxias will be 
provided, including several novel ataxia genes identified by 
our and other groups. These novel ataxia genes provide 
insights into underlying pathways, and also putative future 
biomarkers and treatments. Second, we will show that such 
NGS results yield not only constructive findings, but also 
warrant a new level of critical interpretation. NGS and 
recent related publications deliver a high number of rare 
variants in known ataxia genes with questionable 
significance, and flag putatively novel putative ataxia genes 
which are not yet sufficiently validated. Third, we will show 
that NGS does not make clinical ataxia expertise 
dispensable, but, on the contrary, warrants a new level of 
specific clinical expertise. A high degree of clinical ataxia 
specialist knowledge is indispensable to reliably interpret 
the variant lists produced by NGS. Moreover, we will show 
how clinical hints allow to pinpoint the genetic diagnosis in 
ataxias even before and without NGS.
Disclosure: Matthis Synofzik has received speaker 
honoraria and research support by Actelion Pharmaceuticals. 
He was awarded a Else Kröner Memorial Stipend by the 
Else Kröner-Fresenius Stiftung.
 
FW15-2
Atypical parkinsonian syndromes: rapidly 
expanding genetic disease spectrum, yet 
distinct clinical and imaging signatures
H. Houlden
London, United Kingdom
Parkinsonism is defined by akinesia associated with rigidity 
or rest tremor. The akinesia can be bradykinesia, hypokinesia 
or reduced facial expression. There are a variety of causes 
of parkinsonism, but Parkinson’s disease (PD) is the most 
common. The “atypical parkinsonian syndromes” (called in 
the past “Parkinson’s plus syndromes”) are characterized by 
a rapidly progressive parkinsonism that has a poor or brief 
response to dopaminergic therapy and often with one or 
more atypical features that include; early postural instability/
autonomic failure, supranuclear gaze palsy, pyramidal or 
cerebellar signs, alien limb and apraxia. In addition to the 
usually acquired atypical forms there are an expanding 
group of inherited parkinsonian syndrome such as the 
recessive PLA2G6, FBX07, SPG11, PANK2 and other very 
rare syndromes associated with brain iron where many 
remain genetically undefined. The diagnostic differentiation 
of the atypical parkinsonsian disorders is essential for both 
clinical practice and research because the diagnostic tools 
needed for investigation, prognosis and treatments differ 
significantly to PD. Atypical parkinsonian disorders have a 
shorter survival time and more complications. Drug and 
surgical therapies differ significantly and there are few 
effective treatments. However, early identification of the 
different atypical parkinsonian disorders can reduce 
complications, inform prognosis and allow patients to be 
enrolled in clinical trials. Genetic testing and imaging 
signatures are becoming increasingly important tools in 
which to become adept, and along with clinical skills are 
essential to the movement disorder specialist in clinical 
practice and for research.
Disclosure: Nothing to disclose
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FW15-3
Motor neuron disease and spastic 
paraplegias: large-scale exome 
sequencing reveals common 
pathogenetic hubs
R. Schüle
Tübingen, Germany
Motor neuron disease and hereditary spastic paraplegias 
(HSP) comprise a heterogeneous group of degenerative 
diseases affecting the upper and/or lower motor neurons and 
their axonal projections. The increasing availability and 
decreasing cost of whole exome sequencing (WES) and 
whole genome sequencing (WGS) have led to an 
unprecedented discovery rate of novel genes causing these 
rare conditions. Despite the genetic heterogeneity, the 
predilection of motor neurons for the disease pathology and 
the selective vulnerability of long axonal projections, at 
least in HSPs, suggest a shared pathophysiology among the 
genetically defined subtypes of motor neuron disease and 
HSPs. Discovery of novel disease genes by us and others 
over the past few years have opened up our view from a 
gene-centric to a network-centric focus on pathophysiology. 
In this talk, we will discuss recent advances in genetics of 
motor neuron disease and HSPs and will highlight how 
these novel discoveries translate into a better understanding 
of the cellular mechanisms involved. This mechanistic 
approach may open up novel therapeutic targets and 
opportunities. 
Disclosure: Nothing to disclose.
Focused Workshop 16
Syndromes of central visual and 
vestibular disorders
FW16-1
Cortical visual disorders and neglect
C. Kennard
Oxford, United Kingdom
Disorders of the striate and extrastriate cortex lead to a 
multiplicity of visual disorders which range from a 
homonymous hemianopia to very specific visual 
impairments such as prosopagnosia and visuo-spatial 
neglect. Recent behavioural studies along with functional 
brain imaging have shed new light on these disorders and in 
some have offered the prospect for therapeutic interventions.
The commonest visual deficit is homonymous hemianopia 
and several methods have been devised for restoring 
function either of the visual field itself or by behavioural 
modification. The current controversy relating to some of 
these techniques will be discussed. Focal lesions of the 
extrastriate cortex can lead to specific visual deficits of, for 
example, colour (achromatopsia), motion (akinetopsia), 
face (prosopagnosia) and form (visual agnosia) and current 
views of their functional visual localisation will be 
described. Visuo-spatial neglect is no longer considered to 
be a unitary disorder but rather it consists of a number of 
component deficits, with the precise combination varying 
from patient to patient, presumably determined by the exact 
location and extent of brain damage. Mechanisms 
underlying neglect may not be neglect specific ie they may 
occur on their own without neglect. Recognition of these 
component deficits are leading to the introduction of novel 
therapies such as scanning therapy and hemianopic 
patching, inducing shifts in spatial representations, prism 
adaptation and treating non-spatially lateralised deficits 
pharmacologically.
Disclosure: Nothing to disclose.
 
FW16-2
Peripheral vestibular disorders with 
essential bedside testing
B.M. Seemungal
London, United Kingdom
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Central vestibular disorders (from 
brainstem to cortex)
T. Brandt
Munich, Germany
The traditional classification of vestibular disorders is based 
on the anatomical site of the lesion. While it distinguishes 
between the peripheral and the central vestibular system, 
certain weaknesses become apparent when applied 
clinically. For example, peripheral and central lesions may 
cause similar symptoms  such as skew deviation or tilts of 
perceived vertical which originate with unilateral lesions of 
graviceptive pathways from the labyrinth and the vestibular 
nuclei to the midbrain tegmentum and cerebellum. Further, 
disorders of “higher vestibular function” are missing. A 
concept of disorders of higher vestibular function is 
proposed which involve cognition and more than one 
sensory modality. Three conditions exemplify such higher 
disorders: room tilt illusion, spatial hemineglect, and 
bilateral vestibulopathy all of which present with deficits of 
orientation and spatial memory. Further elaboration of such 
disorders of higher multisensory functions with respect to 
lesion site and symptomatology is desirable. The room tilt 
illusion and spatial hemineglect involve vestibular and 
visual function to the extent that both conditions can be 
classified as either disorders of higher vestibular or of 
higher visual functions. A possible way of separating these 
disorders in a first step is to determine whether the causative 
lesion site affects the vestibular or the visual system. For the 
vestibular system this lesion site may be peripheral or 
central.
Disclosure: Nothing to disclose.
Focused Workshop 17
ALS and FTD: two converging 
diseases?
FW17-1
Neuropathology of FTD and ALS - 
comparing the patterns of propagation
J. Brettschneider
Philadelphia, USA
Neurodegenerative diseases share a common pathological 
hallmark – the accumulation of characteristic proteins into 
insoluble aggregates in or among selectively vulnerable 
neurons and glial cells. The disease-related proteins are 
transformed from their normal conformation into fibrillar or 
multimeric species that function as seeds and templates to 
drive non-pathological protein counterparts to adopt a 
similar structural alteration. Neuropathological studies have 
identified that stereotypical patterns of pathology occur in 
various neurodegenerative diseases over time, and that 
progression of these patterns is associated with increasing 
severity of the clinical phenotype. 
Disclosure: Nothing to disclose.
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FW17-2
Assessment of neuropsychology in ALS 
and FTD
T. Bak
Edinburgh, United Kingdom
Cognitive assessment in patients presenting with motor 
symptoms faces particular challenges. Patients’ performance 
is determined not only by their cognitive functions but also 
by their motor impairment: bulbar symptoms influence 
tasks requiring a verbal response (e.g. naming, verbal 
fluency) while tasks involving writing or drawing can be 
compromised by a wide range of motor symptoms, from 
weakness, through tremor, rigidity, akinesia and dystonia to 
apraxia. However, most currently available 
neuropsychological tests assume normal motor performance. 
Hence, they cannot distinguish whether a low score on a 
particular task is due to motor or cognitive dysfunction, a 
crucially important question when assessing the cognitive 
status. In my presentation, I will discuss examples of the 
interference between motor and cognitive functions on 
neuropsychological testing. I will then present a new 
cognitive screening tool, ECAS (Edinburgh Cognitive 
Screen for ALS), specifically developed to assess cognitive 
functions in patients with motor impairment. It has been 
designed to minimize the influence of motor dysfunction 
through tasks requiring only minimal motor input such as 
pointing or yes/no answers. The whole test can be completed 
in a spoken or a written version. As such, the ECAS allows 
an adequate cognitive assessment in patients of the ALS/
FTD spectrum. I will then present an overview of the 
neuropsychological studies in ALS/FTD, focusing on the 
question whether the cognitive picture can be sufficiently 
explained by a combination of ALS and FTD or whether 
ALS/FTD patients show a specific pattern of cognitive 
dysfunction, distinct from that reported in ALS andFTD 
alone.
Disclosure: Nothing to disclose.
 
FW17-3
ALS and FTD: genetics and phenotypes
V. Silani
Milan, Italy
ALS and FTD are since 2006 to be considered a single 
disease: the neuropathology first provided proof and 
genetics largely confirmed and contributed in defining this 
convergence. The discovery of TARDBP and FUS supported 
recognition that ALS and FTD represent overlapping 
clinical syndromes and this convergence has been further 
strengthened by the discovery of C9orf72, Ubiquilin 2 
(UBQLN2) and other genes. It is now accepted that ALS 
constitutes a continuum with FTD, with pure ALS and pure 
FTD at the ends of this spectrum of motor neuron and 
frontotemporal neuron involvement. Intermediate 
phenotypes include ALS with cognitive impairment, ALS 
with behavioural impairment, and ALS-FTD. The clinical 
implications are so relevant both in the subgrouping of the 
patients and in the design of clinical trials that further 
investigations are highly needed for the most accurate 
definition of the cognitive and motor involvement in both 
the diseases. The overlap between ALS and FTD is indeed 
quite intricate, requiring to be identified according to the 
most updated neuropsychological testing (i.e. ECAS) in 
order to further address the most appropriate therapeutical 
strategies. C9orf72 mutations have been significantly 
reported in ALS with cognitive/behavioural changes and 
antisense oligonucleotide (ASO) therapy is now emerging 
as a highly promising approach. Of converse, a subgroup of 
FTD patients (10%) may show some sign of motor neuron 
degeneration, requiring prompt identification to define 
strategies to oppose weakness.
Disclosure: Nothing to disclose.
